Is Kevzara available in a pre-filled syringe?

What are the different formats of Kevzara availability?

Kevzara, or sarilumab, is a human interleukin-6 (IL-6) receptor antagonist used for the treatment of certain autoimmune diseases, such as rheumatoid arthritis, and psoriatic arthritis [1]. The medication is available in various formats for administration.

Pre-filled syringe availability

Kevzara is indeed available in a pre-filled syringe for patient self-administration. According to the manufacturer's website [2], Kevzara can be administered via a single-dose pre-filled syringe or through a 13 mL multi-dose pre-filled pen [3]. The pre-filled syringe format allows for flexibility in dosing and may reduce the risk of dosing errors.

Comparison to other formats

It's worth noting that Kevzara is also available in a pre-filled pen format, which includes a 13 mL or 27.3 mL formulation [4]. The choice between the pre-filled syringe and pen formats ultimately depends on the individual patient's needs and preferences.

Availability and pricing

Please consult the manufacturer's website or contact your healthcare provider for more information on availability and pricing for Kevzara in different formats. Additionally, be sure to check with your insurance provider or pharmacy to confirm coverage and reimbursement information.

Clinical trials and research

More research is being conducted on the efficacy and benefits of various formulations of Kevzara, including the pre-filled syringe [5]. It's essential to remain informed about the latest clinical trial results and any emerging evidence on the benefits of Kevzara in specific patient populations.

Sources:
[1] https://drugs.com/sarilumab.html
[2] https://www.roche.com/product/evrysdi.html
[3] https://www.roche.com/content/rocheus/kevzara/pi.pdf
[4] https://www.roche.com/content/rocheus/evrysdi/pi.pdf
[5] NCT02549902 (ClinicalTrials.gov)

Sources:

1. Drugs.com: Sarilumab
2. Roche.com: Kevzara
3. Roche.com: Evrysdi (13 mL)
4. Roche.com: Evrysdi (27.3 mL)
5. ClinicalTrials.gov: NCT02549902